HilleVax, Inc.

HLVX | $12.53 -3.69% -3.58% 78K

(0.0% 1d) (-28.1% 1m) (-7.7% 1y) (0.0% 2d) (-3.7% 3d) (-16.7% 7d) (48.49% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 623,003,416

Sec Filling | Patents | 62 employees

hillevax is a biopharmaceutical company focused on the development and commercialization of novel vaccines. our initial program, hil-214, is a virus-like particle (vlp) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.

injection vaccine

add to watch list Paper trade email alert is off

Press-releases

HilleVax Reports Full Year 2023 Financial Results and Highlights Recent Company Progress
Published: 2024-03-20 (Crawled : 20:00) - globenewswire.com
HLVX | $12.53 -3.69% -3.58% 78K

| -22.22% | O: -0.56% H: 0.84% C: -0.94%
company year financial results

HilleVax to Present at Guggenheim 6th Annual Biotechnology Conference
Published: 2024-02-05 (Crawled : 21:00) - globenewswire.com
HLVX | $12.53 -3.69% -3.58% 78K

| -14.88% | O: -0.2% H: 3.4% C: 2.79%
conference

HilleVax Announces Executive Management Appointment of Sean McLoughlin as Chief Operating Officer
Published: 2024-01-18 (Crawled : 12:00) - globenewswire.com
HLVX | $12.53 -3.69% -3.58% 78K

| -15.51% | O: 0.54% H: 0.47% C: -2.41%
management

HilleVax and Kangh Announce Exclusive License Agreement for Hexavalent VLP Norovirus Vaccine Candidate Outside of China
Published: 2024-01-08 (Crawled : 12:00) - globenewswire.com
HLVX | $12.53 -3.69% -3.58% 78K

| -17.51% | O: 0.72% H: 2.22% C: 0.33%
candidate vaccine license norovirus agreement china

HilleVax to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Published: 2024-01-03 (Crawled : 00:00) - globenewswire.com
HLVX | $12.53 -3.69% -3.58% 78K

| -16.69% | O: 0.73% H: 5.48% C: 0.92%
conference

Herpes Zoster Market Size and Share to Grow Positively by 2032, Assesses DelveInsight | Leading Companies - Immorna, ICON, Curevo, Green Cross Corporation, ModernaTX, Pfizer, GlaxoSmithKline, Bristol-Myers Squibb
Published: 2023-11-08 (Crawled : 22:00) - prnewswire.com
HLVX | $12.53 -3.69% -3.58% 78K

| -3.91% | O: 1.07% H: 3.34% C: -5.46%
INCY | $52.72 -0.94% -0.91% 2.1M

Health Technology

| -2.48% | O: 0.35% H: 0.22% C: -3.19%
ICLR | $292.02 -0.68% -0.75% 390K

Health Technology

| 13.19% | O: 0.0% H: 0.82% C: -2.88%
companies market

HilleVax to Present at Upcoming Investor Conferences
Published: 2023-11-01 (Crawled : 21:00) - globenewswire.com
HLVX | $12.53 -3.69% -3.58% 78K

| 5.29% | O: 2.35% H: 2.42% C: -0.66%

HilleVax to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference
Published: 2023-09-26 (Crawled : 20:00) - globenewswire.com
HLVX | $12.53 -3.69% -3.58% 78K

| -7.46% | O: 0.0% H: 3.4% C: -0.07%
conference global

HilleVax Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Published: 2023-09-25 (Crawled : 11:00) - globenewswire.com
HLVX | $12.53 -3.69% -3.58% 78K

| -3.91% | O: -0.77% H: 3.28% C: 1.08%
offering

HilleVax Announces Pricing of Public Offering of Common Stock
Published: 2023-09-20 (Crawled : 00:00) - globenewswire.com
HLVX | $12.53 -3.69% -3.58% 78K

| -13.17% | O: -11.57% H: 20.14% C: 14.18%
offering

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0000950170-24-042359	4	2024-04-05	2024-04-05	Sell	S	6000	789776
0000950170-24-042359	4	2024-04-05	2024-04-04	Sell	S	6000	795776
0000950170-24-042359	4	2024-04-05	2024-04-03	Sell	S	6000	801776
0000950170-24-034326	4	2024-03-20	2024-03-20	Sell	S	6000	807776
0000950170-24-034326	4	2024-03-20	2024-03-19	Sell	S	6000	813776
0000950170-24-034326	4	2024-03-20	2024-03-18	Sell	S	6000	819776
0000950170-24-028832	4	2024-03-08	2024-03-08	Sell	S	6000	825776
0000950170-24-028832	4	2024-03-08	2024-03-07	Sell	S	6000	831776
0000950170-24-028832	4	2024-03-08	2024-03-06	Sell	S	6000	837776